New combo therapy targets tough lymphoma
NCT ID NCT06464185
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This study tests a new treatment for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. It combines two immune-based therapies: a bispecific antibody and CAR-T cells. The goal is to see if the combination is safe and helps control the cancer. About 48 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.